Literature DB >> 19396167

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

Jennifer C King1, Jin Xu, John Wongvipat, Haley Hieronymus, Brett S Carver, David H Leung, Barry S Taylor, Chris Sander, Robert D Cardiff, Suzana S Couto, William L Gerald, Charles L Sawyers.   

Abstract

The TMPRSS2-ERG fusion, present in approximately 50% of prostate cancers, is less common in prostatic intraepithelial neoplasia (PIN), raising questions about whether TMPRSS2-ERG contributes to disease initiation. We identified the translational start site of a common TMPRSS2-ERG fusion and showed that transgenic TMPRSS2-ERG mice develop PIN, but only in the context of PI3-kinase pathway activation. TMPRSS2-ERG-positive human tumors are also enriched for PTEN loss, suggesting cooperation in prostate tumorigenesis.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19396167      PMCID： PMC2898503          DOI： 10.1038/ng.371

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


  13 in total

1.  A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo.

Authors:  J Zhang; T Z Thomas; S Kasper; R J Matusik
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

Review 2.  Recurrent gene fusions in prostate cancer.

Authors:  Chandan Kumar-Sinha; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Nat Rev Cancer       Date:  2008-06-19       Impact factor: 60.716

3.  Role of the TMPRSS2-ERG gene fusion in prostate cancer.

Authors:  Scott A Tomlins; Bharathi Laxman; Sooryanarayana Varambally; Xuhong Cao; Jindan Yu; Beth E Helgeson; Qi Cao; John R Prensner; Mark A Rubin; Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

4.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

5.  TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

Authors:  C Sun; A Dobi; A Mohamed; H Li; R L Thangapazham; B Furusato; S Shaheduzzaman; S-H Tan; G Vaidyanathan; E Whitman; D J Hawksworth; Y Chen; M Nau; V Patel; M Vahey; J S Gutkind; T Sreenath; G Petrovics; I A Sesterhenn; D G McLeod; S Srivastava
Journal:  Oncogene       Date:  2008-06-09       Impact factor: 9.867

6.  Identification of prostate cancer modifier pathways using parental strain expression mapping.

Authors:  Qing Xu; Pradip K Majumder; Kenneth Ross; Yeonju Shim; Todd R Golub; Massimo Loda; William R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-31       Impact factor: 11.205

7.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Authors:  Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

8.  A causal role for ERG in neoplastic transformation of prostate epithelium.

Authors:  Olga Klezovitch; Michael Risk; Ilsa Coleman; Jared M Lucas; Manda Null; Lawrence D True; Peter S Nelson; Valeri Vasioukhin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-01       Impact factor: 11.205

9.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

Authors:  Katharine Ellwood-Yen; Thomas G Graeber; John Wongvipat; M Luisa Iruela-Arispe; JianFeng Zhang; Robert Matusik; George V Thomas; Charles L Sawyers
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays.

Authors:  Sameer Jhavar; Alison Reid; Jeremy Clark; Zsofia Kote-Jarai; Timothy Christmas; Alan Thompson; Christopher Woodhouse; Christopher Ogden; Cyril Fisher; Cathy Corbishley; Johann De-Bono; Rosalind Eeles; Daniel Brewer; Colin Cooper
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568
View more
  238 in total

Review 1.  Genomic rearrangements in prostate cancer.

Authors:  Christopher E Barbieri; Mark A Rubin
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

2.  MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling.

Authors:  Bekir Cinar; Filiz Kisaayak Collak; Delia Lopez; Seckin Akgul; Nishit K Mukhopadhyay; Murat Kilicarslan; Daniel G Gioeli; Michael R Freeman
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

3.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.

Authors:  Wendell S Fortson; Shubhalaxmi Kayarthodi; Yasuo Fujimura; Huali Xu; Roland Matthews; William E Grizzle; Veena N Rao; Ganapathy K Bhat; E Shyam P Reddy
Journal:  Int J Oncol       Date:  2011-04-21       Impact factor: 5.650

Review 4.  New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer.

Authors:  Göran Stenman; Mattias K Andersson; Ywonne Andrén
Journal:  Cell Cycle       Date:  2010-08-28       Impact factor: 4.534

5.  SPINK1 protein expression and prostate cancer progression.

Authors:  Richard Flavin; Andreas Pettersson; Whitney K Hendrickson; Michelangelo Fiorentino; Stephen Finn; Lauren Kunz; Gregory L Judson; Rosina Lis; Dyane Bailey; Christopher Fiore; Elizabeth Nuttall; Neil E Martin; Edward Stack; Kathryn L Penney; Jennifer R Rider; Jennifer Sinnott; Christopher Sweeney; Howard D Sesso; Katja Fall; Edward Giovannucci; Philip Kantoff; Meir Stampfer; Massimo Loda; Lorelei A Mucci
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

6.  ERG rearrangement metastasis patterns in locally advanced prostate cancer.

Authors:  Sven Perner; Maria A Svensson; Ruhella R Hossain; John R Day; Jack Groskopf; Ryan C Slaughter; Analee R Jarleborn; Matthias D Hofer; Rainer Kuefer; Francesca Demichelis; David S Rickman; Mark A Rubin
Journal:  Urology       Date:  2010-04       Impact factor: 2.649

7.  ETS gene fusions and prostate cancer.

Authors:  Wei Huang; Michelle Waknitz
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

8.  ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Housheng Hansen He; Sen Chen; Lingfeng He; Fen Ma; Lorelei Mucci; Qianben Wang; Christopher Fiore; Adam G Sowalsky; Massimo Loda; X Shirley Liu; Myles Brown; Steven P Balk; Xin Yuan
Journal:  J Clin Invest       Date:  2013-02-15       Impact factor: 14.808

9.  A unique cytogenetic abnormality, t(2;7)(p13.1;p21.3), in a Philadelphia-positive chronic myeloid leukemia.

Authors:  Walid Al-Achkar; Abdulsamad Wafa; Faten Moassass; Thomas Liehr
Journal:  Oncol Lett       Date:  2012-05-17       Impact factor: 2.967

10.  Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.

Authors:  Scott A Tomlins; Nallasivam Palanisamy; Javed Siddiqui; Arul M Chinnaiyan; Lakshmi P Kunju
Journal:  Arch Pathol Lab Med       Date:  2012-08       Impact factor: 5.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.